Oppenheimer analyst Francois Brisebois reiterated a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price target ...
In a report released today, Francois Brisebois from Oppenheimer reiterated a Buy rating on Aldeyra Therapeutics (ALDX – Research Report), with ...
Hosted on MSN1mon
Oppenheimer lifts Tarsus stock target, impressed by execution and ocular rosacea potentialThe analyst at Oppenheimer, Francois Brisebois, provided insights into the rationale behind the raised price target. The commentary focused on Tarsus Pharmaceuticals' impressive sales figures for ...
In a report, Analyst Francois Brisebois raises Aldeyra to outperform from perform with a $10 price target. Brisebois says he believes "recent clarity from the FDA gives a path forward for ...
Hosted on MSN1mon
Ovid stock plunges to 52-week low, touches $0.59 amid downturnIn other recent news, Ovid Therapeutics Inc has been upgraded from Perform to Outperform by Oppenheimer analyst Francois Brisebois, who has also set a new price target of $4.00. This upgrade comes ...
The conference is being conducted virtually on February 11, 2025. Dr. Brady’s conversation with Francois Brisebois, Managing Director, Senior Biotech Research Analyst, is scheduled to begin at 9 ...
En conclusion, la réitération par Oppenheimer de la note "Surperformance" et de l’objectif de 22$ reflète la confiance dans la stratégie commerciale d’Avadel Pharmaceuticals. Se négociant à 7,82$, ...
The fireside chat, hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer, will take place on Wednesday, February 12, 2025 at 8:00 AM ET. To attend ...
The conference is being conducted virtually on February 11, 2025. Dr. Brady’s conversation with Francois Brisebois, Managing Director, Senior Biotech Research Analyst, is scheduled to begin at 9:20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback